MicroRNA‑106b serves as a prognostic biomarker and is associated with cell proliferation, migration, and invasion in osteosarcoma
Authors:
- 25 July 2019
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (3) , 3342-3348
Abstract
MicroRNAs (miRNAs) have been demonstrated to be involved in tumor progression of various human malignancies. The purpose of this study was to investigate the expression patterns and prognostic value of microRNA‑106b (miR‑106b) in osteosarcoma (OS) and to examine its functional role in OS progression. Reverse transcription‑quantitative PCR (RT‑qPCR) was used to estimate the expression of miR‑106b in OS tissues and cells. The prognostic value of miR‑106b in OS was evaluated by plotting Kaplan‑Meier survival curves and performing Cox analyses. Cell experiments were carried out to examine the effects of miR‑106b on OS cell proliferation, migration, and invasion. The expression of miR‑106b was elevated in both OS tissues and cells compared with the expression in normal control tissues and cells (P<0.001). miR‑106b expression was associated with metastasis (P=0.028) and Tumor‑Node‑Metastasis stage (P=0.017). Patients with high miR‑106b expression levels had a poorer overall survival rate compared with those with low miR‑106b expression levels (log‑rank P=0.001). Multivariate Cox analyses indicated that miR‑106b expression was an independent prognostic factor for patients with OS (hazard ratio=2.769; 95% confidence interval=1.369‑5.599; P=0.005). The results of cell experiments implied that the upregulation of miR‑106b could promote OS cell proliferation, migration and invasion, whereas the downregulation of miR‑106b could suppress these functions (P<0.05). Taken together, this study's results indicated that the overexpression of miR‑106b is associated with a poor prognosis for patients with OS and that overexpression promotes OS cell proliferation, migration, and invasion. This study may provide a novel prognostic biomarker and a candidate therapeutic target for OS treatment.Keywords
This publication has 35 references indexed in Scilit:
- miRNA-205 Is a Candidate Tumor Suppressor that Targets ZEB2 in Renal Cell CarcinomaOncology Research and Treatment, 2014
- miR‐106b is overexpressed in medulloblastomas and interacts directly with PTENNeuropathology and Applied Neurobiology, 2014
- Osteosarcoma treatment – Where do we stand? A state of the art reviewCancer Treatment Reviews, 2014
- miR-106b-25/miR-17-92clusters: Polycistrons with oncogenic roles in hepatocellular carcinomaWorld Journal of Gastroenterology, 2014
- Downregulation of miR‐106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2Cancer Science, 2013
- Cancer incidence and patient survival rates among residents in the Pudong New Area of Shanghai between 2002 and 2006Chinese Journal of Cancer, 2012
- microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASNOncology Letters, 2012
- Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma IntergroupEuropean Journal of Cancer, 2012
- The Epidemiology of Osteosarcoma2009
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001